Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Iris Isufi, MD

Associate Professor of Medicine (Hematology); Co-Director Adult CAR T-Cell Therapy Program, Hematology; Co-Leader, Cellular Therapy Disease Aligned Research Team (DART), Yale Cancer Center; Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center

Contact Information

Iris Isufi, MD

Mailing Address

  • Hematology

    333 Cedar Street FMP 130, PO Box 208032

    New Haven, CT 06520-8032

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Extensive Research Description

Dr. Isufi's clinical work has been in the area of hematologic malignancies and autologous and allogeneic stem cell transplantation for these conditions. As part of the lymphoid malignancy and transplant teams, she developed a strong clinical interest in aggressive lymphomas. She has focused her efforts in treating patients with aggressive lymphomas as part of clinical trials and consolidating their response to treatment with either autologous or allogeneic transplant based on specifics of their disease. She has a research interest in early drug development in lymphoma, and has served as local PI for a variety of industry- and cooperative-group-sponsored lymphoma trials, including phase 1 trials.

Coauthors

Research Interests

Clinical Trials as Topic; Graft vs Host Disease; Lymphoma; Bone Marrow Transplantation; Clinical Trials, Phase I as Topic; Transplantation Conditioning

Selected Publications

Clinical Trials

ConditionsStudy Title
LungAn Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer
Non-Hodgkin's LymphomaA Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Multiple MyelomaNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Non-Hodgkin's LymphomaA Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Non-Hodgkin's LymphomaA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Lymphoid LeukemiaA Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Anus; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Hodgkin's Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Phase I; Unknown Sites; Breast; Cervix; Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Immune System; Infectious DiseasesMulticenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Hodgkin's Lymphoma; Lymphoid LeukemiaA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Non-Hodgkin's LymphomaA Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma
Edit Profile